This three-part series explores the potential of modeling and simulation practice throughout the drug development process. Part 1 discussed the concept of lifecycle modeling and simulation and its current applications in early drug development. Part 2 considers expanding applications in Phases I-III, including portfolio management. Part 3 will examine modeling and simulation practice and potential in the post-approval arena, including applications aimed at improving healthcare planning and delivery.
White Paper October 04, 2012